Dholka, Gujarat, India
CPL Biologicals completed construction in June of 2010 on its vaccine manufacturing plant in Dholka, India. The 25,000-sf facility will utilize virus-like particle (VLP) technology to produce commercial-scale quantities of influenza vaccines. The plant will be able to produce over 60 million doses annually at full capacity. Ground was broken on the project in fall of 2009. CPL Biologicals is a joint venture of Novavax and Cadila Pharmaceuticals of India.
